Skip to content
You are now leaving to visit

Akcea and Ionis Announce Approval of WAYLIVRA® (volanesorsen) in the European Union

WAYLIVRA is the only therapy for Familial Chylomicronemia Syndrome, or FCS, a devastating, ultra-rare disease BOSTON and CARLSBAD, Calif., May 07, 2019 (GLOBE NEWSWIRE) — Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc.